Vor Biopharma Inc. (VOR) stock
VORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$18.18−0.79 (-4.16%)
Close on Nov 17, 2026Market cap $1.12BP/E –Yield –
Vor Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Vor Biopharma's operating income for the twelve months ending Sep 30, 2026 was -$177.42M. For fiscal 2025 it was -$371.64M. The highest annual figure on record is -$43.37M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$371.64M | – |
| FY2024 | Dec 31, 2024 | -$121.19M | – |
| FY2023 | Dec 31, 2023 | -$126.04M | – |
| FY2022 | Dec 31, 2022 | -$93.42M | – |
| FY2021 | Dec 31, 2021 | -$69.02M | – |
| FY2020 | Dec 31, 2020 | -$43.37M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$58.44M | – |
| Q2 FY2026 | Jun 30, 2026 | -$47.85M | – |
| Q1 FY2026 | Mar 31, 2026 | -$35.16M | – |
| Q4 FY2025 | Dec 31, 2025 | -$35.96M | – |
| Q3 FY2025 | Sep 30, 2025 | -$28.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$274.28M | – |
| Q1 FY2025 | Mar 31, 2025 | -$33.29M | – |
| Q4 FY2024 | Dec 31, 2024 | -$31.31M | – |
| Q3 FY2024 | Sep 30, 2024 | -$28.51M | – |
| Q2 FY2024 | Jun 30, 2024 | -$29.04M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.33M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.12M | – |
| Q3 FY2023 | Sep 30, 2023 | -$35.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$32.17M | – |
| Q1 FY2023 | Mar 31, 2023 | -$30.42M | – |
| Q4 FY2022 | Dec 31, 2022 | -$24.73M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$21.79M | – |
| Q1 FY2022 | Mar 31, 2022 | -$22.80M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.31M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.38M | – |
| Q1 FY2021 | Mar 31, 2021 | -$13.73M | – |
| Q4 FY2020 | Dec 31, 2020 | -$15.66M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.79M | – |
| Q2 FY2020 | Jun 30, 2020 | -$8.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.88M | – |
See a number that looks wrong?